Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: An Underutilized Strategy

Alexander A. Parikh, Shenghua Ni, Tatsuki Koyama, Timothy M. Pawlik, David Penson

Research output: Contribution to journalArticle

Abstract

Objective: Advances in multimodality therapy have led to increased survival for patients with metastatic colorectal cancer, but the impact on patients undergoing resection for colorectal liver metastases is unclear. The purpose of this study was to evaluate patterns of treatment for resectable colorectal liver metastases in the USA over the last two decades. Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, 1,926 patients who underwent hepatic resection for colorectal liver metastasis between 1991 and 2007 were included and divided into two cohorts: period 1 (1991-2000) and period 2 (2001-2007). Demographic data, treatment patterns, and outcomes of the two periods were compared by univariate methods. Multivariable regression models were constructed to predict the use of perioperative chemotherapy, postoperative complications, and 90-day mortality following liver resection. Results: The overall use of perioperative chemotherapy was 33 % and did not differ between periods, but shifted from postoperative to preoperative over time. By multivariable analysis, older age, black race, stage III primary cancer, and metachronous disease were predictive of lesser likelihood of chemotherapy use. The use of preoperative chemotherapy was not associated with any increase in perioperative morbidity or mortality. Conclusions: Despite increased survival and widespread recommendations for the use of multimodality therapy, the overall resection rate and use of perioperative chemotherapy for resectable colorectal liver metastases remain underutilized and have not increased over time. Efforts to investigate barriers to the widespread use of multimodality therapy for these patients are warranted.

Original languageEnglish (US)
Pages (from-to)1938-1946
Number of pages9
JournalJournal of Gastrointestinal Surgery
Volume17
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Neoplasm Metastasis
Liver
Drug Therapy
Therapeutics
Survival
Mortality
Medicare
Postoperative Period
Colorectal Neoplasms
Epidemiology
Demography
Databases
Morbidity
Neoplasms

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Hepatic resection

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases : An Underutilized Strategy. / Parikh, Alexander A.; Ni, Shenghua; Koyama, Tatsuki; Pawlik, Timothy M.; Penson, David.

In: Journal of Gastrointestinal Surgery, Vol. 17, No. 11, 11.2013, p. 1938-1946.

Research output: Contribution to journalArticle

Parikh, Alexander A. ; Ni, Shenghua ; Koyama, Tatsuki ; Pawlik, Timothy M. ; Penson, David. / Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases : An Underutilized Strategy. In: Journal of Gastrointestinal Surgery. 2013 ; Vol. 17, No. 11. pp. 1938-1946.
@article{40ebd5b6344e41eaadd466b72a69db6a,
title = "Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: An Underutilized Strategy",
abstract = "Objective: Advances in multimodality therapy have led to increased survival for patients with metastatic colorectal cancer, but the impact on patients undergoing resection for colorectal liver metastases is unclear. The purpose of this study was to evaluate patterns of treatment for resectable colorectal liver metastases in the USA over the last two decades. Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, 1,926 patients who underwent hepatic resection for colorectal liver metastasis between 1991 and 2007 were included and divided into two cohorts: period 1 (1991-2000) and period 2 (2001-2007). Demographic data, treatment patterns, and outcomes of the two periods were compared by univariate methods. Multivariable regression models were constructed to predict the use of perioperative chemotherapy, postoperative complications, and 90-day mortality following liver resection. Results: The overall use of perioperative chemotherapy was 33 {\%} and did not differ between periods, but shifted from postoperative to preoperative over time. By multivariable analysis, older age, black race, stage III primary cancer, and metachronous disease were predictive of lesser likelihood of chemotherapy use. The use of preoperative chemotherapy was not associated with any increase in perioperative morbidity or mortality. Conclusions: Despite increased survival and widespread recommendations for the use of multimodality therapy, the overall resection rate and use of perioperative chemotherapy for resectable colorectal liver metastases remain underutilized and have not increased over time. Efforts to investigate barriers to the widespread use of multimodality therapy for these patients are warranted.",
keywords = "Chemotherapy, Colorectal cancer, Hepatic resection",
author = "Parikh, {Alexander A.} and Shenghua Ni and Tatsuki Koyama and Pawlik, {Timothy M.} and David Penson",
year = "2013",
month = "11",
doi = "10.1007/s11605-013-2325-z",
language = "English (US)",
volume = "17",
pages = "1938--1946",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases

T2 - An Underutilized Strategy

AU - Parikh, Alexander A.

AU - Ni, Shenghua

AU - Koyama, Tatsuki

AU - Pawlik, Timothy M.

AU - Penson, David

PY - 2013/11

Y1 - 2013/11

N2 - Objective: Advances in multimodality therapy have led to increased survival for patients with metastatic colorectal cancer, but the impact on patients undergoing resection for colorectal liver metastases is unclear. The purpose of this study was to evaluate patterns of treatment for resectable colorectal liver metastases in the USA over the last two decades. Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, 1,926 patients who underwent hepatic resection for colorectal liver metastasis between 1991 and 2007 were included and divided into two cohorts: period 1 (1991-2000) and period 2 (2001-2007). Demographic data, treatment patterns, and outcomes of the two periods were compared by univariate methods. Multivariable regression models were constructed to predict the use of perioperative chemotherapy, postoperative complications, and 90-day mortality following liver resection. Results: The overall use of perioperative chemotherapy was 33 % and did not differ between periods, but shifted from postoperative to preoperative over time. By multivariable analysis, older age, black race, stage III primary cancer, and metachronous disease were predictive of lesser likelihood of chemotherapy use. The use of preoperative chemotherapy was not associated with any increase in perioperative morbidity or mortality. Conclusions: Despite increased survival and widespread recommendations for the use of multimodality therapy, the overall resection rate and use of perioperative chemotherapy for resectable colorectal liver metastases remain underutilized and have not increased over time. Efforts to investigate barriers to the widespread use of multimodality therapy for these patients are warranted.

AB - Objective: Advances in multimodality therapy have led to increased survival for patients with metastatic colorectal cancer, but the impact on patients undergoing resection for colorectal liver metastases is unclear. The purpose of this study was to evaluate patterns of treatment for resectable colorectal liver metastases in the USA over the last two decades. Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, 1,926 patients who underwent hepatic resection for colorectal liver metastasis between 1991 and 2007 were included and divided into two cohorts: period 1 (1991-2000) and period 2 (2001-2007). Demographic data, treatment patterns, and outcomes of the two periods were compared by univariate methods. Multivariable regression models were constructed to predict the use of perioperative chemotherapy, postoperative complications, and 90-day mortality following liver resection. Results: The overall use of perioperative chemotherapy was 33 % and did not differ between periods, but shifted from postoperative to preoperative over time. By multivariable analysis, older age, black race, stage III primary cancer, and metachronous disease were predictive of lesser likelihood of chemotherapy use. The use of preoperative chemotherapy was not associated with any increase in perioperative morbidity or mortality. Conclusions: Despite increased survival and widespread recommendations for the use of multimodality therapy, the overall resection rate and use of perioperative chemotherapy for resectable colorectal liver metastases remain underutilized and have not increased over time. Efforts to investigate barriers to the widespread use of multimodality therapy for these patients are warranted.

KW - Chemotherapy

KW - Colorectal cancer

KW - Hepatic resection

UR - http://www.scopus.com/inward/record.url?scp=84885956405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885956405&partnerID=8YFLogxK

U2 - 10.1007/s11605-013-2325-z

DO - 10.1007/s11605-013-2325-z

M3 - Article

C2 - 24018590

AN - SCOPUS:84885956405

VL - 17

SP - 1938

EP - 1946

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -